Alector's Drug Fails: Stock Plummets, Future Uncertain
Update: 2025-10-21
Description
Alector's stock price crashed after its Phase 3 trial for latozinemab, a frontotemporal dementia drug, failed. The company is halting latozinemab programs, laying off 45% of staff, and its research head is resigning. Alector is now focusing on its Alzheimer's drug, nivisnebart, and other brain disease therapies, with enough funding to last several years.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
